InsidersTradesSigma
Track the BALCHEM CORP stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Chemicals & Materials sector, BALCHEM CORP has recorded 162 insider filings. Market capitalisation: €5.2bn. The latest transaction was disclosed on 13 February 2026 (Attribution). Among the most active insiders: Backus William A.. The full history is openly available.
162
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€4m
10 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BALCHEM CORP Buy (bullish), based on 4 analysts. Average price target: US$200.75.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,636 of 29,062 companies
55.3
score / 100
Value42
Quality69
FCF yld3.1%
Earn yld2.7%
EV/EBITDA22.9x
ROE13%
Gross mgn36%
Net mgn15%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 February 2026
Declarations162 total
430 shares0Common StockSEC:0001140361-26-005544:0
940 shares0Common StockSEC:0001140361-26-005542:0
7,350 shares0Common StockSEC:0001140361-26-005536:0
700 shares0Common StockSEC:0001140361-26-005533:0
490 shares0Common StockSEC:0001140361-26-005531:0
2,870 shares0Common StockSEC:0001140361-26-005520:0
1,200 shares0Common StockSEC:0001140361-26-005516:0
1,710 shares0Common StockSEC:0001140361-26-005512:0
3,610 shares0Common StockSEC:0001140361-26-005510:0
870 shares0Common StockSEC:0001140361-26-005436:0
870 shares0Common StockSEC:0001140361-26-005435:0
870 shares0Common StockSEC:0001140361-26-005434:0
870 shares0Common StockSEC:0001140361-26-005433:0
870 shares0Common StockSEC:0001140361-26-005432:0
870 shares0Common StockSEC:0001140361-26-005431:0
322 shares@ US$173.162.0% of flowCommon StockSEC:0001140361-26-004642:0
343 shares@ US$173.1618.6% of flowCommon StockSEC:0001140361-26-004619:0
383 shares@ US$167.242.5% of flowCommon StockSEC:0001140361-26-004618:0
3,225 shares@ US$173.1612.0% of flowCommon StockSEC:0001140361-26-004617:0
430 shares@ US$173.1630.5% of flowCommon StockSEC:0001140361-26-004616:0
416 shares@ US$173.1619.4% of flowCommon StockSEC:0001140361-26-004615:0
258 shares@ US$173.162.8% of flowCommon StockSEC:0001140361-26-004614:0
863 shares@ US$173.1616.8% of flowCommon StockSEC:0001140361-26-004613:0
373 shares@ US$173.1610.6% of flowCommon StockSEC:0001140361-26-004612:0
3,383 shares@ US$74.5713.1% of flowCommon StockSEC:0001140361-25-044554:0
25 of 162 declarations
关于 BALCHEM CORP
Balchem Corp.（股票代码BCPC）是一家在美国纳斯达克上市的公司，对于寻求美国股票敞口的投资者而言，它是一个值得关注的名字。公司总部位于新泽西州蒙特维尔，其历史可追溯到1967年，由企业家和投资者创立。随着时间的推移，Balchem已发展成为高性能配料和赋能技术的专业供应商，其商业模式以配方科学、包封、螯合和营养相关化学为中心，而非大宗化学品敞口。([balchem.com](https://balchem.com/our-company/)) 如今，Balchem通过三个主要报告部门运营：人类营养与健康、动物营养与健康以及特种产品。人类营养与健康为食品和饮料应用、补充剂以及某些药物用途提供定制的配料系统，以及关键营养素和输送系统。动物营养与健康是核心战略特许经营业务，公司称其为胆碱生产、营养包封、螯合矿物质和功能性配料领域的全球领导者，这些产品广泛应用于反刍动物、猪、家禽、水产养殖和伴侣动物。特种产品涵盖更具技术性的应用，包括高性能气体和其他工业终端市场。([sec.gov](https://www.sec.gov/Archives/edgar/data/0000009326/000000932626000016/exhibit991-q12026.htm?utm_source=openai)) 从竞争角度来看，Balchem的吸引力在于其利基市场的领导地位和技术差异化。公司强调其长期专业知识、专有产品系统和广泛的制造足迹，称其包括22个全球制造基地和8个全球研发技术中心。这种规模支持了客户亲密度、产品创新和供应链弹性，同时使Balchem能够通过单一的特种配料平台服务多个终端市场。([balchem.com](https://balchem.com/our-company/)) 产品组合以品牌和专业平台为核心，例如VitaCholine®、K2VITAL™、Optifolin+®、OptiMSM®以及Balchem的微胶囊产品，包括BakeShure®、ConfecShure®和MeatShure®。这些品牌之所以重要，是因为它们强化了Balchem作为解决方案提供商而非简单配料供应商的定位，帮助公司在性能、配方支持和最终用途效益方面实现差异化。公司还一直在投资品牌建设和面向客户的数字资产，包括2025年推出的新产品品牌网站。([balchem.com](https://balchem.com/wp-content/uploads/2025/04/Balchem-Q1-2025-Earnings-Release.pdf)) 近期企业发展凸显了这一战略方向。2025年12月，Balchem宣布在纽约奥兰治县新建一座高产能微胶囊制造工厂，预计于2027年投产，旨在扩大其食品配料技术的产能。管理层表示，该项目建立在五十多年专业知识的基础上，并巩固了公司在美国的立足点。与此同时，Balchem持续报告稳健的运营势头，2025年实现了创纪录的季度销售额和EBITDA，这得益于所有三个部门的增长。公司还强调了欧盟对中国进口胆碱氯化物的反倾销关税，这对其欧洲胆碱相关业务可能是一个有利的发展。([balchem.com](https://balchem.com/news/hnh-new-microencapsulation-facility/))
